Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Primary Study Objective:
To assess the pathological complete response rate (pCR) with 4-6 cycles of neoadjuvant
chemotherapy plus erlotinib in patients with triple negative breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Kansas University of Kansas Medical Center